Chimerix (CMRX) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Conference overview

• H.C. Wainwright hosted its 26th Annual Global Investment Conference, featuring presentations, panels, and one-on-one meetings across multiple sectors.

• Chimerix CEO presented updates on oncology programs, focusing on dordaviprone (ONC201) and ONC206, and discussed financial rights to TEMBEXA.

Dordaviprone (ONC201) clinical progress

• Phase II data in H3K27M-mutant diffuse midline glioma showed a 30% overall response rate and 40% disease control rate in a 50-patient cohort.

• Durable responses observed, with some patients exceeding 18 months survival in a population with expected median survival under six months.

• Safety profile is favorable, with low rates of severe adverse events and minimal need for dose modification or discontinuation.

• Phase III ACTION study is enrolling 450 newly diagnosed patients globally, with interim data expected in Q3 2025.

• Market opportunity estimated at $750 million globally, with patent protection extending to 2037 and potential for further extension.

Pipeline and future opportunities

• ONC206, a second-generation imipridone, shows 10x higher in vitro potency and promising preclinical and early clinical results in CNS and non-CNS tumors.

• Dose escalation studies ongoing, with most adverse events mild to moderate and no unexpected safety issues at current dose levels.

• Potential for ONC206 to move into primary efficacy studies pending successful completion of phase I cohorts.